The poster presented at the meeting will be made available on the Glucotrack website following the conference.

Explore the advantages of continuous glucose monitors and their reliance on precise electronic components for accurate data ...

The U.S. FDA cleared Senseonic Holdings Inc.’s Eversense 365, the first continuous glucose monitor to last a full year with a single sensor rather than the 10 days to two weeks typical for wearable ...

Establishing the PAB aims to keep patients’ insights at the forefront of Glucotrack’s development plans for its long-term implantable Continuous Blood Glucose Monitor (CBGM). “Similar to ...

RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people ...

On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device ...

Establishing the PAB aims to keep patients' insights at the forefront of Glucotrack's development plans for its long-term implantable Continuous Blood Glucose Monitor (CBGM). “Similar to ...

The Eversense sensor is implanted subcutaneously into the upper ... based on real-time readings from the sensor and predicted glucose levels. The twiist system is set to be available in select ...

Glucotrack's CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration.